These studies and our data suggest that anti-EPOR antibodies inhibit the binding of EPO to EPOR and then suppress the signaling for cardioprotection, resulting in left ventricular hypertrophy and a reduction in cardiac systolic contractility in patients on HD. This evidence concerns the gene EPO and left ventricular hypertrophy.